Innate Pharma moves forward anti-KIR monoclonal antibody IPH 2101 development with study extension in acute myeloid leukemia
Innate Pharma reports Phase II clinical data with IPH 1101 in oncology
Description of the Company’s authorization to purchase of its own shares adopted during the general shareholders’ meeting on june 23, 2009
Innate Pharma enters into a liquidity agreement with Natixis Securities
Innate Pharma announces that it will participate to the MidCap Event on 21-22 September, 2009.
Inserm Transfert and Innate Pharma enter into an innovative partnership for the development of new antibodies for the treatment of cancer and inflammatory or autoimmune diseases
Financial results for the first half of 2009: significant investment in clinical programs and cash position reinforced
Start of the first Phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 million euros financing from Oséo
Innate Pharma reports positive Phase IIa clinical results for IPH 1101 (γδT cell agonist) in type C viral hepatitis
Innate Pharma announces today the outcome of its annual general meeting, including changes in the composition of its Supervisory Board
